NEWARK, Del, April 12, 2023 (GLOBE NEWSWIRE) -- During the forecast period 2023 to 2033, the Vutrisiran Market is expected to grow at a value of 12% CAGR, according to Future Market Insights. By the year 2033, the global market for Vutrisiran is expected to rise up to a market valuation of US$ 2087 Million. The growth of the market can be attributed to Vutrisiran offering hope and a new treatment option for patients with hereditary transthyretin-mediated amyloidosis (hATTR).
the launch of Vutrisiran, patients with hATTR have a new, promising treatment option that addresses the underlying cause of the disease. Vutrisiran is a small interfering RNA (siRNA) molecule that works by inhibiting the production of abnormal TTR protein, which is responsible for the buildup of amyloid deposits. By reducing the production of abnormal TTR, Vutrisiran slows down the progression of the disease and improves the quality of life for patients.
Get a Full PDF Sample Copy of the Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16993
The launch of Vutrisiran is a significant milestone in the field of hATTR treatment. The medication has shown promising results in clinical trials, demonstrating its safety and efficacy in reducing TTR protein levels and improving clinical outcomes in patients. In a Phase III clinical trial, Vutrisiran was found to reduce TTR protein levels by 85% on average, and nearly all patients experienced a significant improvement in their neurological symptoms.
The launch of Vutrisiran is a game-changer for the hATTR market, as it offers a new and effective treatment option for patients with this devastating disease. The medication has the potential to improve the lives of thousands of individuals living with hATTR and their families by slowing down the progression of the disease and improving clinical outcomes.
Key Takeaways from the Market Study
- The global Vutrisiran market is expected to grow with a 12% CAGR during 2023 to 2033.
- Hospital pharmacies are expected to hold 46% of the market share in 2023 for Vutrisiran market.
- North America is expected to possess 45% market share for Vutrisiran market in 2023.
- Europe vutrisiran market size is expected to possess 41% market share in 2023.
“The safety and efficacy of Vutrisiran have been demonstrated in clinical trials. Owing to this, key players are investing in the development of vutrisiran,” states an FMI analyst
Are you looking for customized information related to the latest trends, drivers, and challenges? Speak to Our Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16993
Competitive Landscape
Key players in the vutrisiran market are Alnylam Pharmaceuticals, Inc., Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals
- Alnylam Pharmaceuticals has a strong pipeline of other RNAi-based therapies in development for a range of diseases. The success of Vutrisiran has helped to drive investor confidence in the company and increase funding for its other pipeline drugs, which could result in new treatment options for patients.
- Alnylam Pharmaceuticals has established patient access programs to ensure that patients who need Vutrisiran have access to the drug. These programs provide financial assistance, support services, and other resources to help patients access and afford Vutrisiran.
Key Segments Profiled in the Vutrisiran Industry Survey
Drug Class:
- Antisense Oligonucleotides
- Nucleic Acids
- Nucleotide
- Nucleosides
Route of Administration:
- Injectable
- Parenteral
- Subcutaneous
Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Click here today to buy your full report @ https://www.futuremarketinsights.com/checkout/16993
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Vutrisiran market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Drug Class (Antisense Oligonucleotides, Nucleic Acids, Nucleotide, Nucleosides) Route of Administration (Injectable, Parenteral, Subcutaneous) Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)
Table of Content
1. Executive Summary | Vutrisiran Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
Complete TOC with Report Preview @ https://www.futuremarketinsights.com/reports/vutrisiran-market
Have a Look at Related Research Reports in the Healthcare Domain:
Autoimmune Disease Testing Market Size - The global autoimmune disease testing market size is estimated to grow from US$ 6.07 billion in 2023 to US$ 15.75 billion by 2033. FMI projects that the global demand for autoimmune disease testing could exhibit a CAGR of 10% from 2023 to 2033.
Cerebral Vein Thrombosis Treatment Market Share - The global cerebral vein thrombosis treatment market garnered a market value of US$ 170.55 million in 2022 and is expected to accumulate a market value of US$ 611 million by registering a CAGR of 12.3% in the forecast period 2023 to 2033.
Acrylic Teeth Market Growth - Acrylic teeth market revenue is expected to develop from US$ 440.39 million in 2023 to US$ 995.72 million by 2033. A CAGR of 8.5% is expected from 2023 to 2033.
Respiratory Distress Syndrome Management Market Forecast - The global respiratory distress syndrome management market is slated to reach a valuation of US$ 115.4 billion in 2023. According to Future Market Insights, the market is expected to grow at a 4.41% CAGR until 2033, valued at US$ 177.7 billion.
Skull Clamp Market Demand - The skull clamp market is likely to capture a valuation of US$ 2.14 billion in 2023 and is predicted to reach US$ 5.07 billion by 2033. The market is registering a CAGR of 9% during the forecast period.
About Future Market Insights, Inc.
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S., and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
